Heteroaryl Compounds Targeting EGFR Exon 20 Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations are resistant to existing EGFR inhibitors, such as gefitinib and erlotinib, due to the unaltered ATP-binding pocket in these mutants, leading to hyperactivation of downstream signaling pathways and treatment resistance.
Innovation Solution
Development of compounds that selectively inhibit mutant EGFR and HER2 proteins with exon 20 insertions, including specific chemical structures represented by Formula I, which can effectively target and modulate these proteins, thereby inhibiting their kinase activity and associated cancerous signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EGFR inhibitors (gefitinib, erlotinib) are used to treat NSCLC with EGFR exon 20 insertion mutations, then treatment is administered, but the treatment is ineffective due to resistance caused by unaltered ATP-binding pocket in mutant EGFR
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target the unique conformational state of exon 20 mutant EGFR. The compounds contain heteroaryl groups and specific substituent patterns (R1-R12) that enable selective binding to the altered kinase domain structure of mutant EGFR, while maintaining selectivity against wild-type EGFR and other kinases. This localized structural adaptation allows the compounds to overcome the resistance mechanism.
Solution Approach 2:
The patent employs parameter changes by modifying chemical structure parameters (molecular weight, logP, polar surface area, pKa) to optimize compound properties for penetrating the blood-brain barrier and achieving selective inhibition. The compounds are designed with specific molecular weight ranges (350-650 Da) and lipophilicity (logP 2-5) to enhance CNS penetration while maintaining selective binding to mutant EGFR conformational states.
2Reliability
If compounds are designed to selectively inhibit mutant EGFR, then selectivity for mutant over wild-type EGFR is achieved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the compound into distinct functional modules: a core heteroaryl structure (Formula I), substituent groups (R1-R12) with specific functions, and pharmacophore elements. This modular design allows systematic optimization of selectivity and penetration properties while maintaining manageable structural complexity. The segmented approach enables rational design of compounds with tailored properties for mutant EGFR inhibition and CNS penetration.
3Speed
If compounds are developed to penetrate blood-brain barrier, then CNS penetration is improved, but molecular weight and structural constraints increase
Solution Approach 1:
The patent systematically optimizes physical-chemical parameters (molecular weight 350-650 Da, logP 2-5, polar surface area 60-140 Ų, pKa 4-9) to achieve optimal blood-brain barrier penetration. These parameter ranges are specifically designed to balance CNS penetration capability with selective inhibition of mutant EGFR, ensuring compounds can cross the blood-brain barrier while maintaining therapeutic selectivity.
Data Source
AI summary
Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.